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ABSTRACT
Background: Extending a previous Phase I study, we report the results of a second 
Phase I autologous tumor cell vaccination trial for patients with recurrent glioblastomas 
(IND 14379-101, NCT01550523).
Methods: Following surgery, subjects were treated by 24 hour implantation in the 
rectus sheath of ten biodiffusion chambers containing irradiated autologous tumor cells 
and IGF-1R AS ODN with the objective of stimulating tumor immunity. Patients were 
monitored for safety, clinical and radiographic as well as immune responses.
Results: There were no Grade 3 toxicities related to protocol treatment and overall 
median survival from initial diagnosis was 91.4 weeks. Two protocol survival cohorts 
with median survivals of 48.2 and 10 weeks were identified and predicted by our 
pre-treatment assessments of immune function, corroborated by post-vaccination 
pro-inflammatory cytokine profiles. Longer survival subjects had imaging findings 
including transient elevations in cerebral blood volume (rCBV) and sustained elevations 
of apparent diffusion coefficient (ADC) interpreted as transient hyperemia and cell loss. 
Conclusions: The vaccine paradigm was well-tolerated with a favorable median 
survival. Our data support this as a novel treatment paradigm that promotes anti-tumor 
immunity.
KEYWORDS
Decompressive Hemicraniectomy, Intracerebral Hemorrhage, Malignant MCA Stroke, 
Traumatic Brain Injury, Aneurysmal Subarachnoid Hemorrhage, Intracranial Pressure, 
Herniation
INTRODUCTION
WHO Grade IV astrocytoma (glioblastoma) is a uniformly fatal primary intracranial malig-
nancy with a median survival of 14 months.1 We conducted an earlier pilot Phase I vaccine 
trial in patients with high grade astrocytomas2 and designed a replacement Phase 1 trial 
with optimized reagents, expanded radiographic response criteria, and new exploratory 
objectives.
METHODS
Study Site and Patients
The study was conducted at Thomas Jefferson University and reached target accrual 
of 12 patients in 14 months. Criteria for enrollment included age > 18, a Karnofsky 
performance score of 60 or better, and 
no co-morbidities that would preclude 
elective surgical re-resection. Twelve 
patients were enrolled for treatment after 
failure from standard therapy.1 A summary 
of enrolled patients, and all available perti-
nent data is included in Table 1.
Study Design and Objectives
As before, the combination product 
consisted of autologous tumor cells 
removed at surgery then treated over-
night with the IGF-1R AS ODN (4mg/ml) 
prior to being added to semi-permeable 
chambers and irradiated.2 Enhance-
ments to the vaccine product included 
use of an 18-mer IGF-1R AS ODN with 
the sequence 5’-TCCTCCGGAGC-
CAGACTT-3’, two frameshifts upstream 
from the previous sequence; and, based 
on data showing that the AS ODN has 
immunomodulatory properties,3,4 addi-
tion of 2 mg of exogenous antisense to 
the chambers (C-v). The protocol was 
also amended to include an eleventh 
control chamber containing PBS (C-p). 
Study objectives included assessment 
of safety and radiographic responses as 
well as exploratory objectives looking at 
immune function and response.
Radiological Assessments
Serial imaging assessments were 
performed on Philips 1.5T and 3T MRIs 
and GE 1.5 T MRIs. Routine anatomic MRI 
features were evaluated as well as physi-
ologic measurements including dynamic 
susceptibility weighted (DSC) MR perfu-
sion and 15-direction diffusion tensor 
imaging (DTI) were also utilized. 
Immunological Assessments
Plasma leukopheresis was performed 
one week before surgery for baseline 
assessment of immune function. Blood 
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rated as low, moderate and strong and 
staining patterns described as focal or 
diffuse.
Cytokine/chemokine levels in tumor cell 
supernatant were analyzed by Luminex 
kits as designated above. Membranes 
from paired vaccine and control cham-
bers were embedded in paraffin for 
standard immunohistopathologic exami-
nation. Post-mortem autopsy was limited 
to examination of the brain and findings 
were compared to archival paraffin 
blocks of previously treated or untreated 
glioblastomas diagnosed at autopsy.
Statistical Analysis
The level of statistical significance 
between quantitative measures in 
different samples was determined by a 
two-tailed unpaired t-test or matched 
pairs t-test with p < .05. Survival analysis 
was performed by Kaplan-Meier analysis 
and significance established by log 
rank comparisons. All statistical analysis 
including mixture discriminant analysis 
was performed with JMP v. 11 software 
(SAS, North Carolina).
12-myristate,13 acetate (PMA) and iono-
mycin as previously described.6 PBMC 
from glioblastoma patients and normal 
donors were cultured for 24 hours at 37°C 
and 5% CO2 in AIMV media containing 
10% fetal bovine serum (Gibco). Non-
adherent lymphocytes were transferred 
to new plates in order to eliminate 
non-specific effects of contaminating 
monocytes. Lymphocyte cultures were 
stimulated with phorbol 12-myristate 
13-acetate (PMA, 100 ng/ml) and iono-
mycin (0.1 mM, both from Sigma-Aldrich) 
for 18 hours. BD Golgiplug™ (1:1000, 
Brefeldin A, BD Bioscience) was added 
during the last 6 hours of culture to 
permit cytokine accumulation. 
Tumor tissue sections were assessed 
by immunohistochemistry or immuno-
fluorescence, adapting the method of 
Emoto7, for GFAP, IGF-1R, CD163, CD14, 
CD3, CD4, and CD8. Immunopositive 
cells were counted quantitatively with 
Aperio or qualitatively by an experienced 
neuropathologist (LEK) using an ordinal 
scale from 0 (no staining) to 6 (strong 
diffuse staining) with staining intensity 
was obtained post-operatively on days 
7, 14, 28, 42, 56, and every 3 months 
after vaccination. Sera and cell fractions 
were separated by centrifugation and 
cells were treated with red blood cell 
lysis buffer and white blood cells either 
quantified by flow cytometry or stored 
in DMSO at -80°C. Serum samples were 
also stored at -80°C. Flow cytometry 
was performed as previously described5 
using an EasyCyte 8HT (Millipore) and 
fluorescently-conjugated mAb specific 
for human CD4, CD8,CD11b, CD14, 
CD16, CD20, CD45, CD56, CD80, CD83, 
and CD 86 (all from BD Biosciences), and 
CD163 (R&D Systems). Post- collection 
analysis was performed with FlowJo 
software (Tree Star Inc, Ashland, OR). 
Serum cytokine factors were quantified 
using Luminex bead arrays (human cyto-
kine/chemokine panels I, II, and III from 
Millipore and HCMBMAG/ MILLIPLEX 
Mag Cancer multiplex assay (emdmilli-
pore.com). This included 6 serum markers 
for glioma related to stem cell function 
including DKK-1, NSE, Osteonectin, 
Periostin, YKL-40, and TWEAK. T-cell 
stimulation was performed with phorbol 
Table 1.  Summary of Patients Enrolled.
Subject Age KPS Interval between 
surgeries (weeks)
# chambers 
implanted
Original lymphocyte 
count (cells/mm2)
Lymphocyte count 
at enrollment 
(cells/mm2)
Previous 
treatments
IDH-1 mutation/ 
MGMT methylation
TJ01 39 70 177 10 N/A 400 S,RT + TMZ, Bev -/
TJ02 57 80 90 9 N/A 1570 S,RT + TMZ -/methylated
TJ03 75 70 32 7 700 300 S,RT + TMZ -/
TJ06/R1 66 80 54 8 2000 1300 S,RT + TMZ -/
TJ07 43 80 215 10 500 430 S, RT + TMZ, 
Bev; RTOG 0525
+/
TJ08 55 80 52 8 1000 500 S,RT + TMZ -/
TJ09 57 80 61 7 1400 300 S, RT + TMZ, 
RTOG 0929
-/unmethylated
TJ10 47 60 376 7 N/A 1800 S, RT + TMZ, Bev -/methylated
TJ11 39 70 32 11* 2400 200 S, RT + TMZ -/
TJ12 60 80 74 7 1100 600 S, RT + TMZ, 
Panobinostat
-/
TJ13 64 80 182 11 N/A 2100 S, RT + TMZ -/
TJ14/R 77 90 30 7/11 1800 1100 S, RT + TMZ -/unmethylated
1Compassionate retreatment; *Protocol amendment to include control chamber filled with phosphate buffered saline; S: surgery; RT: radiation therapy; 
TMZ: temozolamide chemotherapy; Bev: bevacizumab chemotherapy; IDH-1: isocitrate dehydrogenase-1
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Actual CD4 and CD8 T cell counts as well 
as DC counts were significantly higher in 
the longer cohort compared to the short 
cohort. There was a significant correlation 
between CD4 and DC cells and between 
CD4 and CXCL12 only in the longer 
cohort. Coordinated changes between 
circulating levels of T cells, monocytes, 
and pro-inflammatory chemokines/cyto-
kines after vaccination were seen in three 
of four longer cohort subjects. 
As a distinguishing feature differentiating 
the cohorts, peripheral blood cells from 
the longer survival subjects manifested 
significantly higher Th-1 cytokine produc-
tion including IFN-g after stimulation with 
PMA and ionomycin from PBMC obtained 
on day 14. 
Levels of circulating lymphocytes were 
significantly decreased (p<0.0001) in all 
GBM patients when compared to normal 
subject samples (Figure 1A, left panel) and 
the medians of both patient populations 
fell outside of the normal range (Figure 
1A, gray lines). Patients in this same cohort 
exhibited significantly higher levels of 
monocytes (Figure 1A, right panel, p<0.05), 
but the medians of these cell populations 
fell within normal range. 
The mere presence of a given cell 
subset is not enough to ensure proper 
immune function. The cell must also be 
able to respond to stimuli and produce 
at the primary tumor site and slower 
progression. Examples of anatomic 
responses in both cohorts is included 
noted in Figure 2A&B. Physiologic MRI 
measurements augmented these anatomic 
observations for both cohorts is featured 
in Figure 2C&D. Sequential DSC MR perfu-
sion was performed in 7 patients, including 
3 longer-term survivors (TJ03, TJ06, and 
TJ09) who had a paradoxical increase in 
rCBV while improving clinically; however, 
this effect was transient and there was 
a more sustained decrease in rCBV. 
Sequential 15 directions DTI data included 
two long-term survivors (TJ03 and TJ06) 
who showed ADC values increasing in the 
affected hemisphere, reflecting loss of 
tumor cellularity associated with disease 
regression. 
Immunologic Response 
Assessments after Vaccination by 
Survival Cohort
Levels of 24 of the 78 cytokines/chemo-
kines assessed were significantly higher 
in serum from the longer survival cohort 
compared to the short cohort. A spike in 
serum CCL2 occurred after surgery but 
was absent at re-operation in two patients. 
CCL2 levels remained significantly higher 
throughout the post-operative period in 
the short survival cohort. These post-
operative spikes were highly correlated 
with TNF-a spikes. (data not shown).
RESULTS
Safety Assessment and Clinical 
Course
Only one SAE was related to the protocol 
(femoral vein thrombosis after leuko-
pheresis). Nine patients succumbed to 
tumor progression while three patients 
died from other causes. Five autopsies 
were performed.
Median overall survival from initial diag-
nosis was 91.4 weeks which compared 
favorably to other recurrent glioma 
immunotherapy trials.8-13 Two signifi-
cantly different protocol survival cohorts 
of 48.2 and 10 weeks were identified 
as longer and short survival cohorts, 
respectively (Figure 1A&B). Excluding 
one outlier (TJ03), we documented a 
significant correlation between protocol 
survival and degree of lymphopenia at 
enrollment (Figure 1C). Comparison of 
CBC values at initial diagnosis and at 
protocol enrollment indicated that the 
mean lymphocyte count had dropped 
significantly (65%) after standard therapy 
(N=8, p = .012, paired t-test). 
Radiographic Responses
Routine MRI features were assessed 
as previously described.2 In the longer 
survivors we noted diminished size 
of enhancement and FLAIR envelope 
Figure 1.  Survival Metrics.
A. Overall survival of patients in trial; B. protocol survival with two survival cohorts; Nine patients died of disease progression while one died 
of intracerebral hemorrhage and two of sepsis. Overall protocol survival was 48.2 weeks and 9.2 weeks, respectively for longer (N = 4) and 
short (N = 8) survival cohorts (log-rank = .014). C. Excluding one outlier and three non-disease-related deaths linear regression revealed high 
correlation between protocol survival and lymphocyte count at enrollment (R2 = .8, p = .0028).
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(Figure 1C, left panel). Furthermore, 
recursive partitioning analyses identified 
two different populations (R2=0.547) of 
recurrent GBM patients enrolled in our 
clinical trial (Figure 1C, right panel). 
Reanalyzing these data focusing on 
single parameters based on the func-
tional immune capacity confirmed the 
highly significant differences identified 
by recursive partitioning (Supplementary 
Figure 1). Patients with higher immune 
function possessed 3-fold higher levels of 
lymphocytes (p<0.0001) and half as many 
monocytes (p<0.005) when compared to 
the lower functioning group (Supplemen-
tary Figure 1). In addition to higher levels 
of lymphocytes, the T cells from patients 
with higher immune function produced 
twice as much IFN-g following stimulation 
patients with primary and recurrent GBM 
produced significantly less IFN-g when 
compared to normal controls (p< 0.01), 
but there was no difference between 
GBM patient cohorts (Figure 1B, right 
panel). 
Moreover, while a difference in the 
quantity of IFN-g produced by the T cells 
was observed, there was no difference in 
the frequency of IFN-g+ T cells between 
these two cohorts (data not shown). In 
order to assess the relationship between 
lymphocyte numbers and immune func-
tional capacity, we performed linear 
regression analyses. Lower levels of 
circulating lymphocytes are associated 
with a statistically significant (R2=0.508, 
p=0.0093) decrease in IFN-g production 
following PMA/ionomycin stimulation 
appropriate immune modulators. 
T-helper type 1 immunity is consid-
ered to be the appropriate anti-tumor 
immune response. Cultures of non-
adherent lymphocytes were stimulated 
nonspecifically with phorbol 12-myristate 
13-acetate (PMA) and ionomycin over-
night in order to stimulate the production 
of IFN-g, the prototypical Th1 cytokine 
which was detected by intracellular 
cytokine flow cytometry. Viable, CD3+ 
T cell-specific gates were established 
(Figure 1B) and the median fluorescence 
intensity (MFI) of IFN-g+ T cells was 
normalized to T cells that did not produce 
cytokine (IFN-g+ T cells). PMA/ionomycin 
stimulation of normal T cells resulted in a 
26-fold increase in the IFN-g MFI (Figure 
1B, right panel). T cells enriched from 
Figure 2.  Radiographic responses with associated physiologic measurements and cytokine profiles.
A. Examples of short survival cohort. TJ11: A-D; TJ10: E-H. A,E: pre-operative T1-gadolinium-enhanced axial images; G: T1-gadolinium-
enhanced coronal image; C: pre-operative axial FLAIR image. B,D,F,H: respective 3 month post-operative images. B. Examples of longer 
survival cohort. TJ06: A-D: TJ09: E-H. A,E: pre-operative T1-gadolinium-enhanced axial images; C,F: pre-operative axial FLAIR images. 
B,D,F,H: respective 3 month post-operative images. C. Relationship between relative cerebral blood volume in tumor v. apparent diffusion 
coefficient in short survival cohort. D. Relationship between relative cerebral blood volume in tumor v. apparent diffusion coefficient in 
longer survival cohort; there is a high correlation between the ADC and rCBV (R2 = .96, p = .0005).
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Figure 3.  Functional immune capacity varies in glioblastoma patients.   
A. Lymphocyte and monocyte frequencies are expressed as a percentage of white blood cells as determined by clinical blood counts 
performed by Thomas Jefferson University Hospital. Frequencies in trial patients are compared to primary glioblastoma patients and 
normal blood donors. Scatter dot plots indicate the mean frequency and standard deviation. Statistical significance of differences between 
tumor patients and normal blood donors were assessed by ANOVA followed by Dunnett’s post-test (****p<0.0001 and *p<0.05). Gray 
lines represent the upper and lower range of normal values. GBM signifies newly diagnosed patients; GBMr signifies recurrent glioblastoma 
patients. B. Non-adherent peripheral blood mononuclear cells were stimulated with PMA/ionomycin and cytokine production was assessed 
by intracellular flow cytometry. Live cell gates were established in forward- and side-scatter plots (left panel). Quadrant gates were used 
to assess IFN-g production in CD3+ T lymphocytes (middle panel). Numbers indicate the frequency of cells in a given quadrant. Median 
fluorescence intensity of IFN-g +CD3+ cells was normalized to IFN-g -CD3+ cells and is presented as a ratio in scatter dot plots (right panel). 
Statistical significance of the difference between tumor patients and normal blood donors was assessed by ANOVA followed by Dunnett’s 
post-test (***p<0.0005). C. Left panel: Recursive partitioning analysis separated the trial patients into groups with higher and lower 
immune functional capacity (R2=0.547). Right panel pair: Linear regression analysis of IFNg production versus peripheral blood lymphocyte 
frequency revealed a significant association of these variables only in the longer survival cohort with a positive correlation (R2=0.83).  
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Evolution of resistance to treatments in 
gliomas has now been associated with 
activation of the IGF-1R signaling axis 
and IGF-1R inhibition through a small 
molecule inhibitor overcomes this resis-
tance with improved outcomes.23 We 
are currently exploring the impact of the 
IGF-1 bioregulatory system in recurrent 
gliomas and the impact of the IGF-1R AS 
ODN in this vaccination paradigm. 
Differences in the radiographic obser-
vations between the longer and short 
survival patient cohorts provide further 
support for the concept that the vacci-
nation paradigm may have an impact on 
the glioma TME. Higher rCBV values are 
typically associated with tumor progres-
sion,24 and MR perfusion had only 
transient increases in the longer cohort, 
a finding not previously described. ADC 
measurements differentiated tumor 
progression (lower values) from what we 
interpreted as cell loss (higher values).25 
In summary, we have established the 
safety profile of an improved combina-
tion glioma vaccine product and have 
documented alterations in immune 
parameters associated with clinical and 
radiographic improvements. Despite 
immune compromise, we documented 
favorable immune responses associated 
with tumor regression and longer survival 
after treatment. To be most effective, 
however, a replacement trial should 
include screens for immune compromise 
and means by which immune function 
could be restored prior to vaccination.
Study Oversight
The physician sponsor (DWA) was 
primarily responsible for the design 
and funding of the study. All authors 
participated in the conduct of the study, 
analysis of the data and the reporting of 
the results. After IRB approval, this study 
was overseen by an independent data 
safety and monitoring board appointed 
by the Sidney Kimmel Cancer Center at 
Thomas Jefferson University.
DWA and DCH have financial interests in 
the Imvax Corporation related to this work. 
higher levels of tumor-specific antibody 
isotypes and cytokines/chemokines 
commonly associated with Th1 immu-
nity including IgG1, IgG3, IL12, CXCL10, 
CXCL12, CCL7, CCL19, and CCL21 not 
seen in the short cohort. 
The short survival cohort had longer 
overall survival perhaps in part due to 
MGMT methylation and better responses 
to temozolamide in three patients. 
However the treatment-induced lympho-
penia and the lower CD4:CD8 ratio could 
perhaps also be ascribed to temozol-
amide. Also, elevated serum CCL2 levels 
found in the short cohort have been 
associated with the mesenchymal gene 
expression profile19 and a poor prog-
nosis20 in glioma patients.
Cytokine production is a hallmark feature 
of immune function in lymphocytes. We 
used phorbol ester-mediated, non-specific 
stimulation of patient lymphocytes in order 
to stimulate maximal cytokine output as a 
surrogate indicator of immune function. 
IFN-g is the classical Th1 cytokine and the 
logical choice for assessing immune fitness 
of T lymphocytes in our GBM patients. 
The amount of IFN-g production by T 
cells following overnight stimulation was 
approximately half the amount produced 
by normal donor cells treated similarly. 
IFN-g production and lymphocyte counts 
were strongly associated and predictively 
identified patients with different levels of 
immune fitness that fell into either the 
longer or short survival cohort. Lympho-
cytes from patients with higher functional 
immune capacity were more frequent 
and produced higher levels of IFN-g that 
approached levels to those produced by 
normal lymphocytes stimulated under 
similar conditions. In contrast, T cells from 
trial patients in the lower immune func-
tion cohort were less in number (50%) and 
unable to respond to PMA stimulation. 
The implanted chambers have inherent 
adjuvanticity. We have confirmed that the 
antisense sequence, its CpG motif, and 
the direct mixture with glioma cells in situ 
effectively initiate anti-tumor immunity3 
also noted by others.21,22 The CpG motif 
specifically interacts with TLR94 causing 
plasmacytoid DC activation, measured 
by CD80 and CD86 expression.5 The 
elevated CD4:CD8 ratio after vaccination 
in the longer survival cohort could reflect 
local TLR9 DC activation and CD4 T cell 
stimulation. 
with PMA/ionomycin (Supplementary 
Figure 1, p<0.01). Subsequent analyses 
will focus on patients with higher/lower 
functional immune capacity. Analysis of 
hospital-acquired blood cell counts fail 
to take in to consideration immune cell 
subsets. We performed flow cytometry 
phenotyping in order to further charac-
terize the white blood cells. Frequencies 
of CD20+ B cells were significantly 
decreased in those patients with lower 
cohort (p<0.005) and fell outside of the 
normal average (Figure 2). CD4+ T cells 
in both cohorts were significantly lower 
than the normal average, while CD14+ 
monocytes were significantly increased 
compared to normal averages (Figure 2) in 
both partitioned cohorts. CD8+ T cells in 
both cohorts were similar to normal aver-
ages (Figure 2). There was no difference 
between the lower and higher cohorts 
with respect to CD4+ or CD8+ T cell, or 
CD14+ monocyte frequencies (Figure 2). 
DISCUSSION
Like its predecessor, the revised 
autologous cell/chamber-based GBM 
vaccination trial did not raise any signifi-
cant safety concerns. We recognized, 
however, that an immunotherapy trial 
for recurrent GBM faces incumbent chal-
lenges. Patients emerging from standard 
therapy for GBM often have severe leuko-
penia,14 which was also documented in 
the current trial. It was therefore not 
surprising that we could not docu-
ment T cell infiltrates in the TME after 
treatment. Surgery itself enhances host 
immune mechanisms favoring tumor 
growth through the attraction of M2 
macrophages to the tumor environment 
postoperatively15,16 suggested by the CCL2 
serum spike provoked by craniotomy. 
Other than this post-operative serum 
spike, the highest levels of CCL2 expres-
sion were found in the tumor supernatants 
during vaccine preparation supporting 
well-documented observations that CCL2 
is produced from cells in the TME.17,18 The 
lack of a CCL2 peak after re-vaccination in 
two patients suggested loss of these cells 
after the first vaccination.
We identified two significantly different 
survival cohorts with different responses 
to this vaccine paradigm allowing us to 
explore the nature of potentially thera-
peutic immune mechanisms. Serum from 
the longer cohort subjects contained 
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